Prosecution Insights
Last updated: November 04, 2026
Application No. 18/003,731

TAU BINDING MOLECULES

Final Rejection §112
Filed
Dec 29, 2022
Priority
Jun 29, 2020 — EU PCT/EP2020/068314 +3 more
Examiner
WANG, CHANG YU
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Gen2 Neuroscience Limited
OA Round
2 (Final)
33%
Grant Probability
At Risk
3-4
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
293 granted / 879 resolved
-26.7% vs TC avg
Strong +54% interview lift
Without
With
+53.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
70 currently pending
Career history
964
Total Applications
across all art units

Statute-Specific Performance

§101
4.7%
-35.3% vs TC avg
§103
27.1%
-12.9% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
35.7%
-4.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 879 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION RESPONSE TO AMENDMENT Status of Application/Amendments/claims 2. Applicant’s amendment filed June 15, 2026 is acknowledged. Claims 1-3, 7-8, 15, 17 and 20-21 are canceled. Claims 4-6, 9, 16, 18, 22 and 24-25 are amended. Claims 4-6, 9-14, 16, 18-19 and 22-25 are pending in this application. Claims 9-14, 18-19 and 24 are withdrawn without traverse (filed 12/08/2025) from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on December 08, 2025. 3. Claims 4-6,16, 22-23 and 25 are under examination with respect to SEQ IDs: 20, 21, 164, 23-25 for HCDRs1-3 and LCDRs1-3 and SEQ ID NOs:186 and 160 for VH and VL(i.e. (a) clone VH4_H04) in this office action. 4. Applicant’s arguments filed on June 15, 2026 have been fully considered but they are not deemed to be persuasive for the reasons set forth below. Specification 5. The objection to the specification is withdrawn in response to Applicant’s amendment to the specification. Claim Rejections/Objections Withdrawn 6. The objection to claims 1-7, and 25 is withdrawn in response to Applicant’s amendment to the claims and cancelation of claims 1-3 and 7. The objection to claims 9-14, 18-19 and 24 is withdrawn in response to Applicant’s amendment to the claims. The rejection of claim 3 on the basis that it contains an improper Markush grouping of alternatives is moot because the claim is canceled. The rejection of claims 3-6 and 22-23 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite is withdrawn in response to Applicant’s amendment to the claims and cancelation of claims 1-3. The rejection of claims 1-3, 6 and 7 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement is withdrawn in response to Applicant’s amendment to the claims and cancelation of claims 1-3 and 7. The rejection of claims 1-2, 7,16 and 25 under 35 U.S.C. 102(a)(1) as being anticipated by Sigurdsson et al. (US2008/0050383) is withdrawn in response to Applicant’s amendment to the claims and cancelation of claims 1-2 and 7. The rejection of claims 22-23 under 35 U.S.C. 103 as being unpatentable over Sigurdsson et al. (US2008/0050383) in view of Wadia et al. (US11472869) and Wasserman et al. (US20200132683) is withdrawn in response to Applicant’s amendment to the claims. The provisional rejection of claims 1-3 and 7 on the ground of nonstatutory double patenting as being unpatentable over claims 8-12, 14-21, 25-31 of copending Application No. 17623577 (the ‘577 Application) in view of Sigurdsson et al. (US2008/0050383) is moot because the claims are canceled. Claim Rejections/Objections Maintained In view of the amendment filed on June 15, 2026, the following rejections are maintained. Improper Markush Grouping 7. Claims 4-6 stand rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). The rejection is maintained for the reasons of record and the reasons set forth below. Briefly, the Markush grouping of different humanized anti-human 2N4R antibodies comprising different SEQ ID NOs: and variants for CDRs1-3 recited in claim 3, the Markush grouping of different humanized anti-human 2N4R antibodies VH4_H04, VH_H02……VH4_H14/L2 comprising different SEQ ID NOs: for HCDR1-3 and LCDR1-3 recited in claim 4 and the Markush grouping of different clone VH4_H04….. Clone VH4VK3(D) recited in claims 5-6 comprising different SEQ ID NOs: for VH and VL are improper because the alternatives defined by the Markush grouping do not share both a single structural similarity and a common use for the following reasons: The recited alternative species do not share a single structural similarity, as each species of humanized anti-human 2N4R antibodies has a different chemical structure because it comprises different amino acid sequences for HCDRs1-3 and LCDRs1-3 or VH and VL. Each antibody has a different binding activity to epitopes. Thus, the antibodies do not share a single structural similarity or biological activity. Accordingly, while the different antibodies are asserted to have the property of being correlated with a neurological or movement disorder or an altered susceptibility thereto, they do not share a single structural similarity essential to this activity. See MPEP § 706.03(y). Response to Amendment On p.11-13 of the response, Applicant argues that each species is a combination of VH and VL sequences that share a single structural similarity and share a common use of binding tau protein for diagnosis, treating or preventing tauopathy. Applicant further cites MPEP2117(II), In re Harnisch, Multilayer Stretch Cling Film Holdings, Inc. v. Berry Plastics Corp and MPEP2117 (IV) and MPEP2117(IV)(b) and Ex parte Dams in support of the arguments. Applicant’s arguments have been fully considered but they are not found persuasive. The recited alternative species do not share a single structural similarity, as each species of humanized antibodies has different amino acid sequences for HCDRs1-3 and LCDRs1-3 or VH and VL (see p.47-48, Table 5) and each species of humanized antibodies has a different binding activity to different epitopes (see p. 65-66, Tables 10-11) of the specification filed 06/15/2026. Thus, the antibodies do not share a single structural similarity or biological activity. Accordingly, while the different antibodies are asserted to have the structural of an antibody and binding to tau for diagnosis, treating or preventing tauopathy, they do not share a single structural similarity essential to this activity. See MPEP § 706.03(y). Thus, the humanized antibodies comprising different sequences do not share a single structural similarity or biological activity. Note that when the Markush grouping is for alternatives of chemical compounds, the alternatives are regarded as being of a similar nature where the following criteria are fulfilled: (A) all alternatives have a common property or activity; AND (B)(1) a common structure is present, that is, a significant structural element is shared by all of the alternatives; OR (B)(2) in cases where the common structure cannot be the unifying criteria, all alternatives belong to a recognized class of chemical compounds in the art to which the invention pertains. The phrase “significant structural element is shared by all of the alternatives” refers to cases where the compounds share a common chemical structure which occupies a large portion of their structures, or in case the compounds have in common only a small portion of their structures, the commonly shared structure constitutes a structurally distinctive portion in view of existing prior art, and the common structure is essential to the common property or activity. The phrase “recognized class of chemical compounds” means that there is an expectation from the knowledge in the art that members of the class will behave in the same way in the context of the claimed invention, i.e. each member could be substituted one for the other, with the expectation that the same intended result would be achieved. In the present situation, there is no evidence of record to establish that it is clear from their very nature of different antibodies having different sequences have a common activity and structure. Accordingly, the rejection of claims 4-6 on the basis that it contains an improper Markush grouping of alternatives is maintained. Claim Rejections - 35 USC § 112 8. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 4-5,16, 22-23 and 25 stand rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. The rejection is maintained for the reasons of record and the reasons set forth below. Claims 4-5,16, 22-23 and 25 as amended encompass a genus of humanized antibodies or antigen-binding fragments thereof comprising recited SEQ ID NOs: in a random manner within the VH and VL. Claim 5 encompasses a genus of humanized antibodies or antigen-binding fragments thereof comprising at least 95%...99% identity to recited SEQ ID NOs: for VH and VL. Claim 25 encompasses is directed to a genus of humanized antibodies or antigen-binding fragments thereof comprising recited SEQ ID NOs: for VH and VL in a random manner and bind to undefined epitopes comprising K375, T377 and R379 or T373, K375, T377 and R379. Briefly, the specification provides no structural and functional relationship between the claimed genus of a genus of humanized antibodies or antigen-binding fragments thereof comprising recited SEQ ID NOs: for VH and VL in a random manner recited in claim 4 and humanized antibody clones VH1VK1….VH5Vk4 with defined HCDRs1-3 and LCDRs1-3 or VH and VL capable of binding to aa 369-381 (SEQ ID NO:1) of human 2N4R tau (1-441 of SEQ ID NO:2) as listed on p. 65-66, Table 10 or p. 81-83, Tables 15-17 of the specification. The instant claims 4-5,16, 22-23 and 25encompass humanized antibodies or antigen-binding fragments comprising recited SEQ ID NOs: in a random manner within the VH and VL and with no defined binding activity or epitope. The specification provides no well-established structural and functional relationship between the claimed genus of humanized antibodies or antigen-binding fragments comprising recited SEQ ID NOs: in a random manner within the VH and VL recited in claim 4 or the claimed genus of humanized antibodies or antigen binding fragments comprising at least 95%..99% identity to recited SEQ ID NOs: for VH and VL recited in claim 5 and the humanized antibody clones VH1VK1….VH5Vk4 with defined HCDRs1-3 and LCDRs1-3 or VH and VL capable of binding to aa 369-381 (SEQ ID NO:1) of human 2N4R tau (1-441 of SEQ ID NO:2) as listed on p. 65-66, Table 10 or p. 81-83, Tables 15-17 of the specification. Thus, a skilled artisan cannot envision the functional correlations of the claimed genus with the claimed invention. Response to Arguments On p.14 of the response, Applicant argues that the rejection has been overcome in view of amendment to the claims to depend from claim 4 or cancelation of claims 1-3 and 7. Applicant's arguments have been fully considered but they are not found persuasive. Contrary to Applicant's arguments, the examiner asserts that based on MPEP §2163, MPEP §§2163.01-2163.03, the specification fails to provide sufficient description or information or evidence to demonstrate that Applicant is in possession of the claimed genus of humanized antibodies or antigen-binding fragments thereof comprising recited SEQ ID NOs: in a random manner within VH and VL as recited in claim 4 or the claimed genus of humanized antibodies or antigen-binding fragments thereof comprising at least 95%...99% identity to recited SEQ ID NOs: for VH and VL with no defined binding activity or epitope recited in claim 5 or the claimed genus of humanized antibodies or antigen-binding fragments thereof comprising recited SEQ ID NOs: in a random manner within the VH and VL and binding to undefined epitopes comprising K375, T377 and R379 or T373, K375, T377 and R379 because: i. There is no structural and functional relationship or correlation between the claimed genus of humanized antibodies or antigen binding fragments comprising recited SEQ ID NOs: in a random manner within the VH and VL with no defined epitopes or binding activity recited in claim 4 and the humanized antibody clones VH1VK1….VH5Vk4 with defined HCDRs1-3 and LCDRs1-3 or VH and VL capable of binding to aa 369-381 (SEQ ID NO:1) of human 2N4R tau (1-441 of SEQ ID NO:2) as shown on p. 65-66, Table 10 or p. 81-83, Tables 15-17 of the specification. There is no structural and functional relationship or correlation between the claimed genus of humanized antibodies or antigen binding fragments comprising at least 95%...99% identity to recited SEQ ID NOs: for VH and VL with no defined binding activity or epitope recited in claim 5 and the humanized antibody clones VH1VK1….VH5Vk4 with defined HCDRs1-3 and LCDRs1-3 or VH and VL capable of binding to aa 369-381 (SEQ ID NO:1) of human 2N4R tau (1-441 of SEQ ID NO:2) as shown on p. 65-66, Table 10 or p. 81-83, Tables 15-17 of the specification. There is no structural and functional relationship or correlation between the claimed genus of humanized antibodies or antigen binding fragments comprising recited SEQ ID NOs: in a random manner within the VH and VL with no defined epitopes comprising undefined K375, T377,and R379 or T373, K375, T377 and R379 recited in claim 25 and the humanized antibody clones VH1VK1….VH5Vk4 with defined HCDRs1-3 and LCDRs1-3 or VH and VL capable of binding to aa 369-381 (SEQ ID NO:1) of human 2N4R tau (1-441 of SEQ ID NO:2) as shown on p. 65-66, Table 10 or p. 81-83, Tables 15-17 of the specification. The specification has not disclosed sufficient species for the broad genus of humanized antibodies or antigen binding fragments thereof recited in claims 4-5 and 25. The specification fails to teach what other structures and sequences and characteristics for the claimed genus of humanized antibodies or antigen binding fragments thereof recited in claims 4-5 and 25. The specification provides no well-established structural and functional relationship between the claimed genus of humanized antibodies or antigen binding fragments thereof recited in claims 4-5 and 25 and the humanized antibody clones VH1VK1….VH5Vk4 with defined HCDRs1-3 and LCDRs1-3 or VH and VL capable of binding to aa 369-381 (SEQ ID NO:1) of human 2N4R tau (1-441 of SEQ ID NO:2) as shown on p. 65-66, Table 10 or p. 81-83, Tables 15-17 of the specification. The specification fails to provide sufficient description or information as to what other common structures and sequences are required by the claimed genus of humanized antibodies or antigen binding fragments thereof recited in claims 4-5 and 25 with no defined binding activity or epitopes. It is not known what can or cannot be changed or included in the claimed genus of humanized antibodies or antigen binding fragments thereof recited in claims 4-5 and 25 to maintain the activity of the claimed genus of humanized antibodies or antigen binding fragments thereof recited in claims 4-5 and 25. Since the common characteristics/features of other humanized antibodies or antigen binding fragments thereof recited in claims 4-5 and 25 are unknown, a skilled artisan cannot envision the functional correlations of the genus with the claimed invention in view of MacCallum et al. (see p. 73; J. Mol. Biol.,1996; 262: 732-745, cited previously). Pascalis et al. (see p. 3079-3080; The Journal of Immunology, 2002; 169: 3076-3084, cited previously), Casset et al. (page 202, left col.; BBRC, 2003; 307: 198-205, cited previously), Vajdos et al. (see p. 416, left col; J. Mol. Biol. 2002; 320: 415-428, cited previously), Holm et al.(Mol. Immunol., 2007; 44: 1075-1084, cited previously), Chen et al. (see p. 866 ; J. Mol. Bio., 1999; 293: 865-881, cited previously), Wu et al. (see p. 152, left col.; J. Mol. Biol., 1999; 294:151-162, cited previously), Burgess et al. (J of Cell Bio. 1990, 111:2129-2138, cited previously), Bowie et al. (see col 2, p. 1306, Bowie et al. Science, 1990, 247:1306-1310, cited previously), Pawson et al. (see p. 445 the second column, first paragraph, Pawson et al. 2003, Science 300:445-452, cited previously), Alaoui-lsmaili et al. (see p. 502, right col., 2th paragraph; Alaoui-lsmaili et al., Cytokine Growth Factor Rev. 2009; 20:501-507, cited previously), Guo et al. (see p. 9207, left col., 2th paragraph, Guo et al., PNAS 2004; 101:9205-9210, cited previously) and Rudikoff et al. (see p. 1979; Proc. Natl. Acad. Sci. USA 1982 Vol. 79: page 1979, cited previously). Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the genus of humanized antibodies or antigen binding fragments thereof recited in claims 4-5 and 25. Based on MPEP § 2161.01 and §2163, “to satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. See, e.g., Moba, B.V. v. Diamond Automation, Inc., 325 F.3d 1306, 1319, 66 USPQ2d 1429, 1438 (Fed. Cir. 2003); Vas-Cath, Inc. v. Mahurkar, 935 F.2d at 1563, 19 USPQ2d at 1116”. Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description' inquiry, whatever is now claimed.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See Vas-Cath at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of humanized antibodies or antigen binding fragments thereof recited in claims 4-5 and 25, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See Fiers v. Revel, 25 USPQ2d 1601 at 1606 (CAFC 1993) and Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. One cannot describe what one has not conceived. See Fiddes v. Baird, 30 USPQ2d 1481 at 1483 and Centocor v. Abbott, 636 F.3d1341 (Fed. Cir. 2011) and AbbVie v. Janssen, 759 F.3d 1285 (Fed. Cir.2014). One cannot describe what one has not conceived. See Fiddes v. Baird, 30 USPQ2d 1481 at 1483. Therefore, the claimed humanized antibodies or antigen binding fragments thereof recited in claims 4-5 and 25 have not met the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115). Applicant is directed to the Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 "Written Description" Requirement. See MPEP § 2161.01 and 2163. Accordingly, the rejection of claims 4-5,16, 22-23 and 25 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement is maintained. New Grounds of Rejection Necessitated by the Amendment The following rejections are new grounds of rejections necessitated by the amendment filed on June 15, 2026. Claim Rejections - 35 USC § 112 9. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 25 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 25 is indefinite because claim 25 recites the limitation "the epitope comprises….and R379 " in lines 2-3 of the claim. There is insufficient antecedent basis for this limitation in the claim. In addition, it is unclear what residues K375, T377 and R379 or T373, K375, T377 and R379 mean and what sequence or what protein and what positions they correspond to. Thus, claim is indefinite. Conclusion Allowable Subject Matter 10. Claim 6 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. 11. Claims 4-5,16, 22-23 and 25 are rejected. 12. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. WO2020260722 teaches an Anti-2N4R tau antibody against human tau epitope aa 369-381 of SEQ ID NO:1 (see the sequence alignment). SEQ ID NO:20-SEQ ID NO:21-SEQ ID NO:164 BIU57750 (NOTE: this sequence has 2 duplicates in the database searched) ID BIU57750 standard; protein; 135 AA. XX AC BIU57750; XX DT 18-FEB-2021 (first entry) XX DE Anti-2N4R tau antibody (Clone 2) heavy chain variable region, SEQ 118. XX KW 2N4R tau; Tau protein; alzheimers disease; antibody production; KW antibody therapy; antimicrobial-gen.; antiparkinsonian; aphasia; KW brain disease; cerebral amyloid angiopathy; cerebroprotective; KW creutzfeldt jakob disease; diagnostic test; down syndrome; KW frontotemporal dementia; genetic-disease-gen.; KW gerstmann straussler scheinker disease; growth-disorder-gen.; KW hallervorden-spatz syndrome; heavy chain variable region; KW immune stimulation; immuno-diagnosis; ischemic stroke; metabolic-gen.; KW monoclonal antibody; motor neurone disease; multi-infarct dementia; KW multiple system atrophy; muscular-gen.; myositis; myotonic dystrophy; KW neuroprotective; niemann pick disease type c; nootropic; KW parkinsons disease dementia; prophylactic to disease; protein detection; KW stroke; therapeutic; traumatic brain injury; vaccine, general; KW vasotropic; vulnerary. XX OS Oryctolagus cuniculus. XX CC PN WO2020260722-A1. XX CC PD 30-DEC-2020. XX CC PF 29-JUN-2020; 2020WO-EP068314. XX PR 28-JUN-2019; 2019GB-00009393. XX CC PA (GENT-) GEN2 NEUROSCI LTD. XX CC PI Livesey FJ, Jones C; XX DR WPI; 2021-01297P/011. XX CC PT New isolated synthetic or recombinant peptide comprising epitope, useful CC PT for preventing or treating tauopathy e.g. Alzheimer's disease, CC PT amyotrophic lateral sclerosis/parkinsonism-dementia complex, argyrophilic CC PT grains disease. XX CC PS Claim 9; SEQ ID NO 118; 98pp; English. XX CC The present invention relates to a novel isolated synthetic or CC recombinant peptide for generating a binding molecule which is used for CC preventing or treating tauopathy in a subject. The epitope comprises an CC amino acid sequence of SEQ ID NO: 1 (see BIU57633) which corresponds to CC residues 369-381 of human tau protein of SEQ ID NO: 2 (see BIU57634). The CC invention further relates to: (1) a binding molecule capable of binding CC specifically to the isolated synthetic or recombinant peptide; (2) an CC antigen-binding protein or antibody or its antigen-binding fragment CC capable of binding specifically to the isolated synthetic or recombinant CC peptide; (3) an isolated recombinant DNA or RNA sequence comprising a CC sequence encoding the isolated recombinant peptide, binding molecule and CC antigen-binding protein; (4) a host cell comprising the DNA or RNA CC sequence; (5) a method for making an isolated recombinant peptide, CC binding molecule or antigen binding protein such as an antibody or its CC fragment; (6) a composition comprising the isolated recombinant peptide, CC binding molecule or antigen binding protein; (7) an immunogenic CC composition or vaccine capable of inducing an immunological response in a CC subject inoculated with the composition; (8) the use of the isolated CC recombinant peptide, binding molecule, antigen-binding protein or CC composition for identifying human tau protein; and (9) a diagnostic kit CC comprising an isolated recombinant peptide, binding molecule, antigen- CC binding protein or composition and a reagent capable of detecting an CC immunological complex which comprises the isolated recombinant peptide CC binding molecule. The isolated recombinant peptide is used for generating CC the binding molecule for preventing or treating tauopathy alzheimer's CC disease, amyotrophic lateral sclerosis/parkinsonism-dementia complex, CC argyrophilic grains disease, beta-propeller protein associated CC neurodegeneration (BPAN), British type amyloid angiopathy, cerebral CC amyloid angiopathy, creutzfeldt-jakob disease, dementia pugilistica, CC diffuse neurofibrillary tangles with calcification, down's syndrome, CC chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), CC gerstmann-straussler-scheinker disease, hallervorden-spatz disease, body CC myositis, multiple system atrophy, myotonic dystrophy, niemann-pick CC disease type C, pick's disease, post encephalitic parkinsonism, primary CC age-related tauopathy (PART), prion protein cerebral amyloid angiopathy, CC progressive subcortical gliosis, progressive supranuclear palsy (PSP), CC globular glial tauopathy, parkinsonism dementia complex of guam, CC progressive non-fluent aphasia, multi-infarct dementia, ischemic stroke, CC traumatic brain injury (TBI) and stroke in the subject. XX SQ Sequence 135 AA; Query Match 75.1%; Score 118.6; Length 135; Best Local Similarity 34.7%; Matches 25; Conservative 2; Mismatches 1; Indels 44; Gaps 2; Qy 1 SYAMA--------------CIDRRGGTFYASWVKG------------------------- 21 ||||| |||||||||||||||| Db 36 SYAMAWVRQAPGKGLEWIGCIDRRGGTFYASWVKGRFTISKTSTTVDLKMTSLTTEDTAT 95 Qy 22 -----DAGSFHP 28 |:|:| | Db 96 YFCARDSGAFDP 107 SEQ ID NO:186 BIU57750 (NOTE: this sequence has 2 duplicates in the database searched) ID BIU57750 standard; protein; 135 AA. XX AC BIU57750; XX DT 18-FEB-2021 (first entry) XX DE Anti-2N4R tau antibody (Clone 2) heavy chain variable region, SEQ 118. XX KW 2N4R tau; Tau protein; alzheimers disease; antibody production; KW antibody therapy; antimicrobial-gen.; antiparkinsonian; aphasia; KW brain disease; cerebral amyloid angiopathy; cerebroprotective; KW creutzfeldt jakob disease; diagnostic test; down syndrome; KW frontotemporal dementia; genetic-disease-gen.; KW gerstmann straussler scheinker disease; growth-disorder-gen.; KW hallervorden-spatz syndrome; heavy chain variable region; KW immune stimulation; immuno-diagnosis; ischemic stroke; metabolic-gen.; KW monoclonal antibody; motor neurone disease; multi-infarct dementia; KW multiple system atrophy; muscular-gen.; myositis; myotonic dystrophy; KW neuroprotective; niemann pick disease type c; nootropic; KW parkinsons disease dementia; prophylactic to disease; protein detection; KW stroke; therapeutic; traumatic brain injury; vaccine, general; KW vasotropic; vulnerary. XX OS Oryctolagus cuniculus. XX CC PN WO2020260722-A1. XX CC PD 30-DEC-2020. XX CC PF 29-JUN-2020; 2020WO-EP068314. XX PR 28-JUN-2019; 2019GB-00009393. XX CC PA (GENT-) GEN2 NEUROSCI LTD. XX CC PI Livesey FJ, Jones C; XX DR WPI; 2021-01297P/011. XX CC PT New isolated synthetic or recombinant peptide comprising epitope, useful CC PT for preventing or treating tauopathy e.g. Alzheimer's disease, CC PT amyotrophic lateral sclerosis/parkinsonism-dementia complex, argyrophilic CC PT grains disease. XX CC PS Claim 9; SEQ ID NO 118; 98pp; English. XX CC The present invention relates to a novel isolated synthetic or CC recombinant peptide for generating a binding molecule which is used for CC preventing or treating tauopathy in a subject. The epitope comprises an CC amino acid sequence of SEQ ID NO: 1 (see BIU57633) which corresponds to CC residues 369-381 of human tau protein of SEQ ID NO: 2 (see BIU57634). The CC invention further relates to: (1) a binding molecule capable of binding CC specifically to the isolated synthetic or recombinant peptide; (2) an CC antigen-binding protein or antibody or its antigen-binding fragment CC capable of binding specifically to the isolated synthetic or recombinant CC peptide; (3) an isolated recombinant DNA or RNA sequence comprising a CC sequence encoding the isolated recombinant peptide, binding molecule and CC antigen-binding protein; (4) a host cell comprising the DNA or RNA CC sequence; (5) a method for making an isolated recombinant peptide, CC binding molecule or antigen binding protein such as an antibody or its CC fragment; (6) a composition comprising the isolated recombinant peptide, CC binding molecule or antigen binding protein; (7) an immunogenic CC composition or vaccine capable of inducing an immunological response in a CC subject inoculated with the composition; (8) the use of the isolated CC recombinant peptide, binding molecule, antigen-binding protein or CC composition for identifying human tau protein; and (9) a diagnostic kit CC comprising an isolated recombinant peptide, binding molecule, antigen- CC binding protein or composition and a reagent capable of detecting an CC immunological complex which comprises the isolated recombinant peptide CC binding molecule. The isolated recombinant peptide is used for generating CC the binding molecule for preventing or treating tauopathy alzheimer's CC disease, amyotrophic lateral sclerosis/parkinsonism-dementia complex, CC argyrophilic grains disease, beta-propeller protein associated CC neurodegeneration (BPAN), British type amyloid angiopathy, cerebral CC amyloid angiopathy, creutzfeldt-jakob disease, dementia pugilistica, CC diffuse neurofibrillary tangles with calcification, down's syndrome, CC chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), CC gerstmann-straussler-scheinker disease, hallervorden-spatz disease, body CC myositis, multiple system atrophy, myotonic dystrophy, niemann-pick CC disease type C, pick's disease, post encephalitic parkinsonism, primary CC age-related tauopathy (PART), prion protein cerebral amyloid angiopathy, CC progressive subcortical gliosis, progressive supranuclear palsy (PSP), CC globular glial tauopathy, parkinsonism dementia complex of guam, CC progressive non-fluent aphasia, multi-infarct dementia, ischemic stroke, CC traumatic brain injury (TBI) and stroke in the subject. XX SQ Sequence 135 AA; Query Match 80.1%; Score 487; Length 135; Best Local Similarity 83.0%; Matches 93; Conservative 7; Mismatches 10; Indels 2; Gaps 1; Qy 4 LQESGPGLVKPSETLSLTCTVSGIDLSSYAMAWVRQAPGKGLEWIGCIDRRGGTFYASWV 63 ::||| || | |:|||||||||||||||||||||||||||||||||||||||||||| Db 9 VEESGGRLVTPGTPLTLTCTVSGIDLSSYAMAWVRQAPGKGLEWIGCIDRRGGTFYASWV 68 Qy 64 KGRFTISKDTSKTTVDLQMTSLTAEDTATYFCARDAGSFHPWGQGTLVTVSS 115 |||||||| : |||||:||||| |||||||||||:|:| ||| |||||||| Db 69 KGRFTISK--TSTTVDLKMTSLTTEDTATYFCARDSGAFDPWGPGTLVTVSS 118 13. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. 14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHANG-YU WANG whose telephone number is (571)272-4521. The examiner can normally be reached Monday-Thursday, 7:00am-5:00pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at 571-272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Chang-Yu Wang October 6, 2026 /CHANG-YU WANG/Primary Examiner, Art Unit 1675
Read full office action

Prosecution Timeline

Dec 29, 2022
Application Filed
Dec 08, 2025
Response after Non-Final Action
Mar 17, 2026
Non-Final Rejection mailed — §112
Jun 15, 2026
Response Filed
Oct 08, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774323
APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF
2y 7m to grant Granted Oct 27, 2026
Patent 12662528
NOVEL ANTI-NOGO-A ANTIBODIES
4y 2m to grant Granted Jun 23, 2026
Patent 12662678
HUMAN ALZHEIMER'S DISEASE AND TRAUMATIC BRAIN INJURY ASSOCIATED TAU VARIANTS AS BIOMARKERS AND METHODS OF USE THEREOF
3y 6m to grant Granted Jun 23, 2026
Patent 12655201
ISOLATED ANTIGEN BINDING PROTEIN AND USE THEREOF
3y 6m to grant Granted Jun 16, 2026
Patent 12653872
MIMOTOPES OF ALPHA-SYNUCLEIN AND VACCINES THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHY
3y 6m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
33%
Grant Probability
87%
With Interview (+53.8%)
3y 10m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 879 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month